Bio-Path (BPTH)

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML). It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial, and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases. Additionally, Bio-Path is working on Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia. The company is also developing Liposomal STAT3 (BP1003), which is in preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.